Longeveron to Present at Emerging Growth Virtual Conference on February 19, 2025

Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company, has announced its participation in the Emerging Growth Virtual Conference, taking place on February 18-19, 2025. The company will present on February 19, 2025, from 3:10 to 3:20 p.m. ET. Interested parties can access the webcast through the 'Events and Presentations' section of Longeveron's website, with the replay available for 180 days following the conference. Questions may be submitted in advance to Questions@EmergingGrowth.com or asked during the event.

Longeveron is developing cellular therapies for life-threatening and chronic aging-related conditions, with a focus on regenerative medicine and cellular therapies. The company's lead investigational product, Lomecel-B™, is an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action, including pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects, with broad potential applications across a spectrum of disease areas.

The company is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B™ development programs have received five distinct and important FDA designations, including Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation for the HLHS program, as well as Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the Alzheimer’s disease program.

Longeveron's presentation at the Emerging Growth Virtual Conference provides an opportunity for the company to engage with investors, analysts, and other stakeholders, showcasing its pipeline, clinical trials, and regulatory milestones. This helps to raise awareness about the company's progress and potential. Additionally, Longeveron has recently completed a Follow-on Equity Offering in the amount of $9.000005 million (July 20, 2024) and another in the amount of $5.248428 million (April 12, 2024), indicating the company's need for capital to fund its research and development efforts, which aligns with its growth plans.

In conclusion, Longeveron's presentation at the Emerging Growth Virtual Conference on February 19, 2025, aligns with the company's overall strategic goals and growth plans by providing an opportunity to engage with investors, raise awareness, network with potential partners, update stakeholders on regulatory milestones and clinical trial progress, and ultimately, drive the company's growth and success.